Ascletis Pharma Inc. has announced the selection of ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, as a candidate for clinical development. According to the company, ASC35 demonstrated approximately 71% greater relative body weight reduction compared to tirzepatide in a head-to-head diet-induced obese mouse study. Ascletis intends to submit an Investigational New Drug Application (IND) for ASC35 to the U.S. Food and Drug Administration in the second quarter of 2026. Results of the clinical trial have not yet been presented, as the IND submission and subsequent clinical studies are planned for the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.